WallStSmart

Triple Flag Precious Metals Corp (TFPM)vsVersamet Royalties Corporation Common Stock (VMET)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Triple Flag Precious Metals Corp generates 559% more annual revenue ($488.58M vs $74.18M). TFPM leads profitability with a 84.3% profit margin vs 49.9%. TFPM trades at a lower P/E of 14.7x. TFPM earns a higher WallStSmart Score of 72/100 (B).

TFPM

Strong Buy

72

out of 100

Grade: B

Growth: 10.0Profit: 8.5Value: 6.0Quality: 9.0
Piotroski: 4/9Altman Z: 18.77

VMET

Buy

60

out of 100

Grade: C+

Growth: 10.0Profit: 8.0Value: 5.3Quality: 4.5
Piotroski: 5/9Altman Z: 1.19

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

TFPM6 strengths · Avg: 10.0/10
Profit MarginProfitability
84.3%10/10

Keeps 84 of every $100 in revenue as profit

Operating MarginProfitability
65.1%10/10

Strong operational efficiency at 65.1%

Revenue GrowthGrowth
37.3%10/10

Revenue surging 37.3% year-over-year

EPS GrowthGrowth
172.2%10/10

Earnings expanding 172.2% YoY

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
18.7710/10

Safe zone — low bankruptcy risk

VMET5 strengths · Avg: 9.6/10
Profit MarginProfitability
49.9%10/10

Keeps 50 of every $100 in revenue as profit

Operating MarginProfitability
58.0%10/10

Strong operational efficiency at 58.0%

Revenue GrowthGrowth
391.9%10/10

Revenue surging 391.9% year-over-year

EPS GrowthGrowth
2123.0%10/10

Earnings expanding 2123.0% YoY

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

TFPM0 concerns · Avg: 0/10

No major concerns identified

VMET2 concerns · Avg: 2.5/10
Market CapQuality
$926.14M3/10

Smaller company, higher risk/reward

Altman Z-ScoreHealth
1.192/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : TFPM

The strongest argument for TFPM centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 84.3% and operating margin at 65.1%. Revenue growth of 37.3% demonstrates continued momentum.

Bull Case : VMET

The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 49.9% and operating margin at 58.0%. Revenue growth of 391.9% demonstrates continued momentum.

Bear Case : TFPM

No major red flags identified for TFPM, but monitor valuation.

Bear Case : VMET

The primary concerns for VMET are Market Cap, Altman Z-Score.

Key Dynamics to Monitor

VMET is growing revenue faster at 391.9% — sustainability is the question.

TFPM generates stronger free cash flow (83M), providing more financial flexibility.

Monitor OTHER PRECIOUS METALS & MINING industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TFPM scores higher overall (72/100 vs 60/100), backed by strong 84.3% margins and 37.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Triple Flag Precious Metals Corp

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Triple Flag Precious Metals Corp (TFPM) is a leading precious metals streaming and royalty company that provides innovative capital solutions to the mining industry by securing a portion of future production. With a well-diversified portfolio across premier mining jurisdictions, TFPM effectively mitigates operational risks while capitalizing on the growing global demand for gold and silver. Its unique financial model not only enhances mining operations but also positions the company to take advantage of favorable market conditions. Backed by a strong management team and a robust balance sheet, Triple Flag offers institutional investors an attractive opportunity for resilience and growth within their commodity allocations.

Visit Website →

Versamet Royalties Corporation Common Stock

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Viamet Pharmaceuticals Corp (VMET) is an innovative biopharmaceutical company dedicated to the development of advanced therapeutics targeting serious diseases, particularly in the areas of fungal infections and oncology, utilizing its proprietary metalloenzyme-based technology platform. With a robust and diversified clinical pipeline supported by strategic partnerships and a comprehensive intellectual property portfolio, Viamet is strategically positioned for significant growth. The company remains focused on addressing critical unmet medical needs and is committed to enhancing shareholder value through continued therapeutic advancements in its specialized areas.

Want to dig deeper into these stocks?